Managed care interface
-
Managed care interface · Jul 2002
Comparative StudyPharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Oral dosage forms are the most common mode of drug delivery in most disease areas. However, cancer therapy is associated predominately with intravenous (IV) chemotherapy. Interest in oral anticancer drugs is growing because they may reduce costs and improve patient satisfaction. ⋯ Medicare must expand its coverage to include legitimate oral chemotherapy, and coverage rules must be clearly communicated to physicians. The adoption of appropriate oral chemotherapy reimbursement standards will probably prompt the pharmaceutical industry to continue research and development of oral dosage forms. Oral therapy can potentially reduce resource utilization and health care system costs, improve drug safety, and enhance patient satisfaction.
-
Managed care interface · Jun 2002
Comparative StudyStats & facts. Centers of excellence and managed care.
-
Managed care interface · Mar 2002
Comparative StudyThe effect of donepezil therapy on health costs in a Medicare managed care plan.
The objective of this study was to estimate the ramifications of donepezil use on the health care costs of a large Medicare managed care plan. Patients with a diagnosis of Alzheimer's disease or related dementia were identified from the claims-and-encounter records of the plan. ⋯ Costs were $4,192 lower for patients receiving longer-term therapy (> or = 270 day supply of donepezil) and $3,579 lower for patients receiving shorter-term therapy when compared with controls. By improving cognitive and daily functioning, donepezil may lower costs by improving medical management.
-
Managed care interface · Feb 2002
Can workers' compensation health costs be controlled by managed care?
Three recent studies provide, for the first time, the information needed to evaluate objectively the cost savings, utilization, worker satisfaction, and productivity differences of network versus nonnetwork care in workers' compensation cases. The authors review these studies and analyze their findings.
-
Managed care interface · Jan 2002
Just what the doctor ordered: avoiding kickback pitfalls with prescription drugs.
Risks associated with the federal antikickback statute increased significantly for the pharmaceutical industry in the 1990s. Manufacturers, physicians, and MCOs must take account of the statute when developing programs that could possibly implicate it. This article provides guidance to the managed care community regarding legal kickback risks in arrangements with pharmaceutical manufacturers.